Business Context and Reporting Period
Company: Rocket Pharmaceuticals, Inc. (RCKT)
Filing Type: Form 8-K (Current Report)
Date of Report: May 7, 2026
Reporting Period: Quarter ended March 31, 2026
Context: The Company announced financial information for the quarter ended March 31, 2026, via a press release furnished as Exhibit 99.1.
Key Financial Metrics
The provided filing text serves as a cover document referencing a press release (Exhibit 99.1) but does not contain specific numerical data. Consequently, the following metrics are not available in the source text:
- Revenue: Not provided in filing text.
- Profit/Loss: Not provided in filing text.
- Cash Flow: Not provided in filing text.
- Margins: Not provided in filing text.
- Debt and Liquidity: Not provided in filing text.
Material Changes
The filing text does not provide specific comparative data or details regarding material changes versus the prior comparable period. Investors must refer to the attached press release (Exhibit 99.1) for this information.
Guidance, Outlook, and Risks
Management Commentary: The filing confirms the announcement of Q1 2026 financial results but does not include specific commentary, guidance, or outlook details within the text provided.
Risks and Contingencies: No specific risks or contingencies are detailed in this excerpt.
Unusual Items: None identified in the provided text.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated May 7, 2026) for actual revenue, net income, and cash position figures.
- Verify the specific details of the "certain financial information" announced for the quarter ended March 31, 2026.
- Check for any forward-looking statements or updated guidance included in the press release but omitted from this 8-K summary.
- Confirm the status of the Company's cash runway and burn rate, as these are critical for a pharmaceutical entity and are not listed in this document.